-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text | Li Yuan
On July 20, Lantern Pharma announced the latest preclinical data of the pancreatic cancer treatment drug LP-184 developed in cooperation with the Pancreatic Cancer Institute of Fox Chase Cancer Center
.
Experimental results showed that in pancreatic tumor xenograft mouse models, LP-184 significantly and rapidly reduced pancreatic tumors by more than 90% within 8 weeks, while untreated mice increased tumor volume by 11 times within 8 weeks Above
.
After 8 weeks of LP-184 treatment, the pancreatic cancer tumor in the mouse model completely resolved (Source: Lantern)
Among them, after 8 weeks of treatment, 1 of the 4 mice treated with LP-184 had tumor disappeared, and the average remaining tumor size of 3 mice was about 7% of the original tumor, and it was smaller than the untreated tumor 146 times
.
LP-184 treatment in an in vivo mouse xenograft model of pancreatic cancer significantly shrinks the tumor (Source: Lantern)
LP-184 is a DNA alkylating agent that exerts a therapeutic effect by destroying the DNA in cancer cells, which usually overexpress certain biomarkers
.
LP-184 mechanism diagram (Source: Lantern)
Lantern believes that LP-184 can selectively destroy DNA in tumors that express high levels of PTGR1 enzyme, and that PTGR1 enzyme is highly expressed in a variety of solid tumors
.
In this study, CRISPR knockout data confirmed that PTGR1 plays a leading role in LP-184 in coordinating tumor responsiveness to LP-184
.
The study used CRISPR editing to silence the PTGR1 gene in pancreatic cancer cells, and the results showed that pancreatic cancer cells had almost no response to LP-184, and those pancreatic cancer cells with PTGR1 expression (not affected by gene editing) had an enhanced response to LP-184 , Pancreatic cancer cells die
And the analysis of the Lantern data platform shows that 35%-40% of pancreatic cancer transcriptomes in clinical databases have up-regulated expression of PTGR1
.
Therefore, the use of specific genetic characteristics to select patients can increase the likelihood of success in clinical trials, and can focus future clinical trials on those patients who are likely to benefit the most from treatment, and ultimately may improve the survival of cancer patients.
Rate
.
Lantern plans to initiate an IND application in the second half of this year to promote phase I clinical trials
.
In addition to pancreatic cancer, LP-184 is also undergoing preclinical development for indications such as prostate cancer, ovarian cancer, and glioblastoma
Reference materials:
[1] Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184 (Source: Lantern)
Original title: Lantern announced the latest data on DNA damage therapy for pancreatic cancer
